These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 12673373)
1. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373 [TBL] [Abstract][Full Text] [Related]
2. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541 [TBL] [Abstract][Full Text] [Related]
3. Infliximab treatment and prognostic factors for response in patients with Crohn's disease. Mendoza JL; García-Paredes J; Cruz Santamaria DM; Lana R; Ramírez Fernández E; Rodríguez Asteaga E; Díaz-Rubio M Rev Esp Enferm Dig; 2002 May; 94(5):269-79. PubMed ID: 12474335 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of Crohn's disease treated with infliximab. Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957 [TBL] [Abstract][Full Text] [Related]
6. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
7. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356 [TBL] [Abstract][Full Text] [Related]
8. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Stephens MC; Shepanski MA; Mamula P; Markowitz JE; Brown KA; Baldassano RN Am J Gastroenterol; 2003 Jan; 98(1):104-11. PubMed ID: 12526944 [TBL] [Abstract][Full Text] [Related]
9. Infliximab in Hispanics: characterization of response to infliximab in an ethnic minority with Crohn's disease. Sánchez JM; Maldonado JC; Torres EA; Rivera C P R Health Sci J; 2005 Mar; 24(1):11-7. PubMed ID: 15895872 [TBL] [Abstract][Full Text] [Related]
10. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882 [TBL] [Abstract][Full Text] [Related]
11. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Sandborn WJ; Hanauer SB Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177 [TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301 [TBL] [Abstract][Full Text] [Related]
13. Infliximab use in luminal Crohn's disease. Richter JA; Bickston SJ Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813 [TBL] [Abstract][Full Text] [Related]
14. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P; Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256 [TBL] [Abstract][Full Text] [Related]
15. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Gao Q; Hogezand RA; Lamers CB; Verspaget HW Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330 [TBL] [Abstract][Full Text] [Related]
17. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. Pearce CB; Lawrance IC J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695 [TBL] [Abstract][Full Text] [Related]
18. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096 [TBL] [Abstract][Full Text] [Related]
19. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study]. Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127 [TBL] [Abstract][Full Text] [Related]